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The present study is the first multicentre Italian study and one of the few European
studies that prospectively evaluated the phenotype of Primary Hyperparathyroidism
(PHPT), the adherence to guidelines and the rate of surgical cure.  It can bring novelty
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The present manuscrit follows compliance with Ethical Standards: i) Conflict of Interest:
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
The authors declare that they have no conflict of interest, ii) Funding: no funding, iii)
Human Research: patients signed a specific informed consent, iv) This study has been
approved by the appropriate institutional and/or national research ethics committee
and has been performed in accordance with the ethical standards as laid down in the
1964 Declaration of Helsinki and its later amendments or comparable ethical
standards.
Federica Saponaro, MD, PHD
Tel.: +39-3204964028
Email: federica.saponaro@gmail.com
Filomena Cetani
Tel: +39-050995040
Email: cetani@endoc.med.unipi.it
Response to Reviewers: Manuscript Number: JENI-D-18-00065
Full Title: Clinical presentation and management of patients with Primary
Hyperparathyroidism in Italy
We thank the reviewers and the editor for their thoughtful comments that we took into
account and made changes in the manuscript accordingly (see tracking in the text).
EDITOR
I think that, in order to compare the Italian picture with other countries, it might be
useful to quote and discuss the following paper recently published in this journal:
-Trombetti A et al: Clinical presentation and management of patients with primary
hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on
neuro-behavioral and cognitive symptoms. J Endocrinol Invest 2016; 39: 567-576.
We kindly thank the editor for this noteworthy suggestion. We changed the text
accordingly and compared our results to those of Trombetti et al. along all the
Discussion section (see tracking).
REVIEWER # 1
In this study the Authors report on the results of a large Italian multicentre prospective
study investigating laboratory, clinical and one-year follow-up data in patients with
PHPT. The Authors investigate the adherence to the latest guideline of the Fourth
International Workshop (2013) for the management of asymptomatic primary
hyperparathyroidism. The main conclusions are as follows.
1.Despite the clear suggestions of both the International and Italian guidelines, the
adherence to them is weak both in the symptomatic and asymptomatic patients’
groups.
2.Despite the lack being among the surgical criteria, the results of imaging studies are
strong predictors of choice between surgical versus conservative approach both within
the symptomatic and also asymptomatic patients groups.
General remarks
This is an important and worthwhile study to measure the impact of PHPT guidelines
on the therapeutic decisions for PHPT patients regarding conservative vs. surgical
approach.
Major remarks
-Approx. 43% of patients were lost for the one-year follow-up. Patients who were
asymptomatic and had negative imaging are probably overrepresented in lost-to-
follow-up group. The impact of the high rate of not being followed, as a study bias
should be discussed.
We thank the reviewer for this comment. Indeed, this group of patients was not lost at
follow-up, but were patients of those centers which did not participate to the second
part of the study (follow-up). It’s not possible to extrapolate the idea that they had a
negative imaging rate higher than that of patients reported in the study. The Centers
that participated at the second part of the study (18/29 as now clearer in the results
section line ≠159) had few patients lost at follow-up.  Of note, the lower number of
Centers participating the second part of the study is already reported in the limitations
(end of discussion).
2. The impact of the results of preoperative imaging investigations (ultrasound and
MIBI-scintigraphy) is a very interesting although not unexpected result of the study.
Throughout the manuscript, it is not always clear whether the positive/negative results
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mean completely negative/completely positive results. What about the discordant
results? Were the discordant results considered as negative or positive?
We thank the reviewer and apologize for the inaccuracy. The negative result means
concordant negative imaging, i.e. both ultrasound and MIBI scan were negative.
Indeed, we did not include the discordant imaging results because we think that we
cannot draw conclusions from them. We now have clarified this point along the text and
in the Table 3.
3. It would be worthwhile to discuss the (probably unjustified or at least too high)
impact of preoperative imaging on the decision making process regarding the choice
between conservative vs. surgical treatment.
We completely agree with the reviewer and we added a paragraph (see tracking) in the
discussion section, citing International Guidelines and a recent American paper by
Wachel et al. on preoperative parathyroid imaging and the decision-making process.
4. Since there are no data about the decision-making process and its main
participants, the reviewer is not confirmed that the endocrinologists are the only
(mainly?) responsible doctors for this low adherence.
We thank the reviewer for the comment. Indeed, we believe that the endocrinologists
are the direct responsible for decision making process in this study, since in all the third
level referring centers included in the study, patients were referred and followed-up
from specialists. However, also the patient’s desire could influence the therapeutic
decision, but unfortunately, we have not these data, as already reported in the
discussion (line ≠292). We clarify this point at line ≠250-251.
Minor remarks
1.Despite the large number of patients with MEN1, no patients with MEN2. This needs
explanation,
We thank the reviewer for this comment. A possible explanation is that MEN2 patients
are primarily referred to the oncology service of the Endocrinology Unit, where the
preoperative evaluation is made for thyroid and parathyroid therapeutic program.
2.The non-cure rate of 6% seems a bit high. This observation probably reflects the
relatively high number of low-volume surgical institutions and would be worthwhile to
analyse.
We agree with to reviewer that the non-cure rate of 6% seems too high. However,
interestingly, although defined as sporadic PHPT patients, 3 had a multiglandular
disease and the histology showed hyperplasia in 2 cases and a double adenoma in
one. Therefore, we can hypothesize that these patients might be familial cases with
insufficient family history information or “de novo” cases of familial forms of PHPT, as
stated in the discussion.  Of note, familial PHPT has a higher non cure rate than
sporadic PHPT .
4.Typing errors
probably either instead of either line 184 ok
Least instead of last Fig 1 ok
REVIEWER # 2
General Comments:
This is an interesting paper focusing on PHPT clinical management among
endocrinologists In Italy. The study demonstrates that a significant number of patients,
either with or without symptoms are not managed according to clinical guidelines.
Some observations ay help to improve the quality of the paper.
Specific comments:
- Page 5, Material and Methods: It is unclear if laboratory evaluations were made
centrally or at the single sites only. If the latter to, how did the authors control for the
potential and expected variability in terms of PTH and vitamin D assays particularly?
We thank the reviewer for this important methodological clarification. The laboratory
evaluation could not be done centrally, but we checked the relative uniformity of lab
tests. Indeed, PTH assays were at least second or third generation and vitamin D
assays were mainly CLIA in each center laboratory. We agree that the best would be to
centrally perform the measurements, but we encountered many technical and logistic
difficulties. We included this point in the study limitations (see discussion).
-There are no data about the type of DXA machines used in the study, nor in terms of
cross-calibration or normal data used to define patients as normal or osteoporotic.
Please, consider this point carefully.
We understand the point of the reviewer and agree that the centralization of the DXA
data would have been the gold standard. However, this was not planned in this study.
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We added this point in the limitation of the study. All the participating centers were third
level endocrinology units and used HOLOGIC or LUNAR DXA machines.
The definition of osteoporosis was made accordingly to the latest international
guidelines for osteoporosis (reference ≠14). We included this clarification in the text in
the Materials and Methods and Results sections.
- The terms "fragility fractures" and "clinical fractures" need to be better defined.
Clinical (symptomatic?) vertebral fractures were then confirmed by X-ray imaging?
Which was the method to define a vertebral fracture?
We thank the reviewer for this comment. Fragility fractures were defined as and
synonymous of symptomatic.  We specified this point in the Materials and Methods
section.
-Table 1 and Table 2: Vitamin D levels were normal in the whole group of patients.
Taking into account the very high prevalence of low vitamin D levels in Italy, this
observation is rather strange. How can the authors explain the data?
We thank the reviewer for this comment. The possible explanation is that the patients
were supplemented with vitamin D supplement (by primary medical care), before
reaching the endocrinologist. Indeed, the majority of the participating centers recorded
the use of vitamin D supplements in the database.
- Table 2: vitamin D levels were low in patients with symptoms, irrespective of PTx/no
PTx. It seems also that only these patients had this problem (see before). Which is the
explanation? Was Low Vitamin D a possible determinant of symptoms?
We thank the reviewer for this comment. We agree with the reviewer that low vitamin D
could be a determinant of symptoms. Indeed, hypovitaminosis seems to be more
prevalent in patients with PHPTthan in geographically matched populations and
correlates with severity of the disease (symptoms). Also the increased levels of 1,25-
dihydroxyvitamin D in PHPT have also been proposed to influence overall vitamin D
status. Possible mechanisms might include an inhibition of the production of vitamin D3
in skin, an inhibition of the production of 25-hydroxyvitamin D in the liver or increased
renal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D and a shorter half-
life of 25-hydroxyvitamin, as discussed in the paper by Silverberg et al. JBMR 2007.
Suggested Reviewers: Sandro Giannini
sandro.giannini@unipd.it
His outstanding papers in the field
Miklos Toth
totmik@gmail.com
His outstanding papers in the field
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Abstract 53 
Purpose: Evaluation of the phenotype of primary hyperparathyroidism (PHPT), adherence to International Guidelines 54 
for parathyroidectomy (PTx), and rate of surgical cure. 55 
Method: From January 2014-January 2016, we performed a prospective, multicenter study in patients with newly 56 
diagnosed PHPT. Biochemical and instrumental data were collected at baseline and during one-year follow-up.  57 
Results: Over the first year we enrolled 604 patients (age 61±14 yrs), mostly women (83%), referred for further 58 
evaluation and treatment advice. Five hundred sixty-six patients had sporadic PHPT (93.7%, age 63±13 yrs]), the 59 
remaining 38 (6.3%, age 41±17 yrs) had familial PHPT. The majority of patients (59%) were asymptomatic. Surgery 60 
was advised in 281 (46.5%). Follow up data were available in 345 patients. Eighty-seven of 158 (55.1%) symptomatic 61 
patients underwent PTx. Sixty-five (53.7%) of 121 asymptomatic patients with at least one criterion for surgery 62 
underwent PTx and 56 (46.3%) were followed without surgery. Negative parathyroid imaging studies predicted a 63 
conservative approach [symptomatic PHPT: OR 18.0 (95% CI 4.2-81.0) p<0.001; asymptomatic PHPT: OR 10.8, (95% 64 
CI3.1-37.15) p<0.001). PTx was also performed in 16 of 66 (25.7%) asymptomatic patients without surgical criteria. 65 
Young age, serum calcium concentration, 24-h urinary calcium, positive parathyroid imaging (either ultrasound or 66 
MIBI scan positive in 75% vs 16.7%, p=0.001) were predictors of parathyroid surgery.  Almost all (94%) of patients 67 
were cured by PTx.  68 
Conclusions: Italian endocrinologists do not follow guidelines for the management of PHPT. Negative parathyroid 69 
imaging studies are strong predictors of a non-surgical approach. PTx is successful in almost all patients. 70 
 71 
 72 
Key words: parathyroidectomy, parathyroid adenoma, serum calcium, parathyroid imaging. 73 
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Introduction 78 
Primary hyperparathyroidism (PHPT) is a common endocrine disease, characterized by increased serum calcium and 79 
high or inappropriately normal serum levels of parathyroid hormone (PTH) [1, 2]. PHPT is prevalent in postmenopausal 80 
women and generally due to a single parathyroid adenoma [3]. Clinical presentation of the disease has changed over the 81 
last decades in those countries where serum calcium biochemical screening has been introduced. Indeed, in these areas 82 
PHPT is commonly diagnosed as an asymptomatic disorder, and a minority of cases are characterized by 83 
hypercalcaemic symptoms, nephrolithiasis, bone disease and neuromuscular weakness [4, 5]. Parathyroidectomy (PTx), 84 
the only definitive cure for PHPT, should be considered in all patients and recommended in symptomatic patients. The 85 
knowledge that even patients with asymptomatic PHPT might experience target organs involvement has led to a long 86 
debate about its appropriate management. [6, 7]. The discussion about the need for surgery in asymptomatic PHPT was 87 
matter of four Workshops in 1990, 2002, 2008 and 2013 [8, 9], which provided internationally accepted guidelines for 88 
PTx in patients with asymptomatic PHPT as well as monitoring for those not undergoing surgery. Some important news 89 
and recommendations were introduced in the last International Workshop, particularly regarding the evaluation of bone 90 
and kidney involvement and the impact on patient’s management [9–13].   91 
Few studies have been focused on the impact of these guidelines on the management of patients with PHPT. In the 92 
present study, we prospectively evaluated the phenotype of PHPT in Italy, the adherence to guidelines and the rate of 93 
surgical cure.   94 
 95 
Materials and methods 96 
Study design  97 
This is a prospective, multicenter study performed in 29 Italian centers for endocrine diseases. Patients with newly 98 
diagnosed PHPT in the period January 2014–January 2015 were enrolled and followed for an additional year.  99 
Patients gave their informed consent and the Institutional Review Board of each participating center approved the study. 100 
Patients and data collection 101 
The diagnosis of PHPT was based on elevated ionized or total serum calcium with increased or inappropriately normal 102 
intact PTH, according to the normal reference range of each Center. 103 
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An ad hoc electronic CRF form was developed and used to record all medical data. The CRF was available online, after 104 
registration and login at the web site www.hyperparanet.org. The research was open to all endocrinologists in the whole 105 
Italian area.   106 
The following clinical data were collected at the baseline visit: age, gender, age at diagnosis, diagnosis of sporadic or 107 
familial PHPT, including diagnosis of multiple endocrine neoplasia (MEN) type 1 (MEN1), 2A (MEN2A) and 4 108 
(MEN4), hyperparathyroidism associated-jaw tumor (HPT-JT), familial isolated hyperparathyroidism (FIHP) and 109 
familial hypocalciuric hypercalcemia (FHH). Major PHPT features were also recorded, including i) hypercalcemic and 110 
neuropsychiatric symptoms ii) symptomatic or asymptomatic nephrolithiasis iii) osteoporosis (T score <-2.5 at any 111 
skeletal site by DXA according the latest st International Italian Guidelines for Osteoporosis [14]) iv) previous fragility 112 
fractures (defined as symptomatic anamnestic records of symptomatic and/or X-ray documented fractures) v) use of 113 
drugs potentially affecting bone metabolism vi) hypertension and major cerebrovascular events. Finally, data about 114 
positive or negative imaging studies (neck ultrasound and/or 99mTc-sestamibi parathyroid scintigraphy), if performed, 115 
and information on therapies were also included in the database. 116 
 117 
Biochemical serum and urinary data were collected at baseline and at the last follow-up visit for measurement of: 118 
albumin-adjusted serum calcium (Alb-Ca), plasma PTH, 25-hydroxyvitamin D [25(OH)D], creatinine, cholesterol, 119 
glucose, triglycerides, 24-h urinary calcium excretion.  120 
After the initial evaluation, the therapeutic planning of each patient with PHPT was selected in the electronic CRF, 121 
choosing between two options i) PTx or ii) surveillance with or without medical treatment. A follow-up information on 122 
treatment received and histology, where appropriate, were gathered.  123 
 124 
Statistical analysis   125 
Results are expressed as means ±SD for continuous variables and median (interquartile range) for non-continuous 126 
variables. The Student's t-test, and the Mann-Whitney test were used to compare the continuous and non-parametric 127 
variables, respectively. The Chi-square test and Fisher test were used for comparison of categorical variables, as 128 
appropriate. A logistic binary regression model was applied to evaluate if age at diagnosis, Alb-Ca, PTH, 24-h urinary 129 
calcium, nephrolithiasis, osteoporosis, fragility fractures and concordant positive parathyroid imaging studies were 130 
determinants of the choice of PTx. A P value < 0.05 was considered statistically significant. Statistical analysis was 131 
carried out using "SPSS Statistics 17.0.1, Chicago, Illinois, USA" and "R, 3.0.2, Auckland, New Zealand". 132 
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RESULTS 133 
From January 2014 to January 2015, 29 Italian Centers of Endocrinology, equally distributed in Northern, Central and 134 
Southern Italy, participated in the study. Clinical, biochemical and instrumental records of 604 patients with a new 135 
diagnosis of PHPT were collected on the web site Hyperparanet. Complete clinical, biochemical, instrumental, 136 
histological and one-year follow-up data were available in 345 patients at 18 Centers. 137 
Baseline evaluation of the whole group 138 
The demographic, clinical and biochemical data are summarized in Table 1. The cohort included 604 patients, 502 139 
(83%) females and 102 (17%) males with a female to male ratio of 4.9:1. The mean age was 61±14 years, with a 140 
percentage of juvenile cases (age ≤25 years) of 2.8% (n=17). In the latter group, the female to male ratio was 141 
significantly lower than in the whole group (1.4:1, P=0.009). 142 
Diagnosis of sporadic PHPT was made in 566 (93.7%) patients and familial PHPT in 38 (6.7%), including 23 cases of 143 
MEN1, 6 cases of FIHP, 3 cases of HPT-JT and 6 cases of FHH. MEN1 gene mutation data were available in 24 cases 144 
and mutations were identified in 20.  145 
At least one of the following features was present in 246 (40.7%) patients: i) nephrolithiasis either symptomatic or 146 
asymptomatic (i.e., discovered at ultrasound evaluation at the initial workout) (n=177, 29.1%); ii) clinical fragility 147 
fractures (n=70, 11.6%); iii) symptoms of hypercalcemia (n=34, 5.6%) as nausea, vomiting and constipation; for the 148 
purpose of the present study these patients were classified as “symptomatic PHPT”. The remaining 358 (59.3%) 149 
patients were asymptomatic. Osteoporosis was detected in 264 (43.7%) of patients and defined accordinggly to the last 150 
International Italian Guidelines for Osteoporosis [14]. A history of hypertension or prior major cerebrovascular events 151 
was present in 178 (29.5%) and 9 (1.5%) patients, respectively.  152 
After the initial evaluation, PTx was recommended in 281 (46.5%) patients, namely 180 of the 246 (73%) symptomatic 153 
and 101of the 358 (28%) asymptomatic patients. 154 
Patients with available follow-up  155 
One-year follow-up data were available in 345 patients from 18 Centers which participated the second part of the study 156 
(Fig.1) [289 (83.8%) females and 56 (16.2%) males (F:M=5.2:1), with a mean age of 63±13 years. One hundred fifty-157 
eight (45.8%) patients had nephrolithiasis, clinical fragility fractures and/or symptoms of hypercalcemia and 187 158 
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(54.2%) were asymptomatic PHPT. The majority of patients (n=331, 95.9%) had sporadic PHPT, and the remaining 14 159 
familial PHPT, including MEN1 (n=8), FIHP (n=4), HPT-JT (n=1) and FHH (n=1).  160 
In the whole group, osteoporosis was found in 152 (44.1%) patients and 44 (12.7%) patients complained of 161 
neuropsychiatric symptoms (fatigue, depression, agitation, apathy, lack of concentration) upon questioning. A history of 162 
hypertension or prior major cerebrovascular events was present in 104 (30.1%) and 5 (1.4%) patients, respectively.  163 
Biochemical data at the baseline visit are reported in Table 1. The characteristics of these patients are similar to those of 164 
the entire cohort of 604 patients, with the exception of 24-h urinary calcium and serum 25OHD concentration which 165 
were lower, and the rate of nephrolithiasis that was higher (Table 1).   166 
PTx was performed in 87 (55.1%) of 158 patients with symptomatic PHPT, the majority (n=71, 82.6%) of them had 167 
nephrolithiasis (Fig.1). Interestingly, despite the general consensus that patients with symptomatic PHPT should 168 
undergo surgery, this treatment was not performed in the remaining 71 (44.9%) patients. In order to understand why 169 
surgery was not performed, we compared patients who underwent PTx and those who did not. We found that the former 170 
(PTx), compared to the latter (no PTx), were younger and had significantly higher mean Alb-Ca, plasma PTH, 24-h 171 
urinary calcium and rate of nephrolithiasis, but a lower rate of fragility fractures (Table 2A).  172 
In the remaining 187 patients with asymptomatic PHPT, PTx was advised based on the 2013 guidelines in 121 (64.7%), 173 
who met at least one criterion for PTx, but surgery was performed only in 65 (53.7%) of them. Criteria for PTX in the 174 
latter group were as follows: serum calcium levels 1 mg above the upper limit of normal range (n=37, 56.9%), 175 
osteoporosis (n=35, 53.8%), age <50 yrs (n=14, 21.5%), 24-h urinary calcium >400 mg (n=14, 21.5%). PTx was not 176 
performed in the remaining 56 (46.3%) patients, who, compared with patients who did surgery, had a significantly 177 
lower rate of serum calcium levels 1 mg above the upper limit of normal range (Table 2B). 178 
PTx group 179 
A total of 279 patients (237 females and 42 males, 158 with symptomatic and 121 with asymptomatic PHPT) had 180 
indications for PTx, but surgery was not performed in 127 (45.5%, 71 with symptomatic and 56 with asymptomatic 181 
PHPT). The latter patients were older and had a significantly lower mean Alb-Ca, plasma PTH, 24-h urinary calcium 182 
and rate of nephrolithiasis, but a higher rate of fragility fractures (Table 2C). It could be hypothesized that in a given 183 
patient the decision of not performing surgery was only based upon the above parameters. Interestingly, we found that 184 
parathyroid imaging studies were performed in a large proportion of patients [one imaging exam in 251/279 (89.9%) 185 
and either ultrasound and MIBI scan in 124/279 (69.3%)] at the initial workout, independently of the therapeutic plan, 186 
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i.e. PTx or no PTx. Therefore, the question arises as to whether the results of parathyroid imaging studies might have 187 
had a role in the decision-making process. To evaluate this hypothesis a multivariate analysis that included also the 188 
results of parathyroid imaging studies was performed in the whole group of patients with indications for surgery. The 189 
analysis showed that older age, lower Alb-Ca and, particularly, a higher rate of negative parathyroid imaging studies 190 
[concordant negative either ultrasound and or MIBI scan (OR 11.8 95% CI 5.1-27.2, p<0.0001) were independent 191 
predictors for the choice of not performing PTx (Table 3). A concordant negative result of parathyroid imaging studies 192 
was also a strong predictor of a conservative approach in the subgroups of patients with either symptomatic [OR 18.0 193 
(95% CI 4.2-81.0) p<0.001] or asymptomatic [OR 10.821, (95% CI3.1-37.15) p<0.001)] PHPT (Table 3). We cannot 194 
exclude that patient’s refusal and comorbidities also accounted for the decision of not undergoing PTx, but 195 
unfortunately participants did not report details on this matter.   196 
PTx was also performed in 16 (25.7%) of 66 patients who did not meet the criteria for surgery. These patients, 197 
compared with those who did not undergo surgery, were younger (63±8 vs 69±8 p=0.012), had higher Alb-Ca 198 
concentration (10.5±0.6 vs 9.9±1.3, P=0.012), 24-h urinary calcium (427±319 vs 201±117, p=0.04), and rate of positive 199 
parathyroid imaging (either ultrasound or MIBI in 75% vs 16.7%, P=0.001). 200 
A total of 168 patients underwent PTx, 164/331 with sporadic and 4/14 with familial PHPT. In the former group, the 201 
histological diagnosis was a single adenoma in 148 cases (90.3%), double adenoma in 6 (3.7%), atypical adenoma in 2 202 
(1.2%), hyperplasia in 5 (3.0%), and carcinoma in 3 (1.8%). In the familial group, a single adenoma was found in one 203 
patient with FIHP, hyperplasia in two with MEN1, and carcinoma in one with HPT-JT.  204 
The large majority (n=158, 94.0%) of patients were cured by PTx. Persistence of PHPT was observed in the remaining 205 
10 patients with apparently sporadic PHPT, in whom the parathyroid histology showed a single adenoma in 7, 206 
hyperplasia in 2, and a double adenoma in one.  207 
No-PTx group 208 
The whole group of 177 patients (71 with symptomatic and 106 asymptomatic PHPT) followed without surgery showed 209 
a stable clinical and biochemical disease during the one-year follow-up. Indeed, there was no statistically significant 210 
difference between baseline and last visit evaluation in Alb-Ca, PTH, 25(OH)D and 24-h urinary calcium (Table 4). 211 
Fourteen patients were treated with cinacalcet and 37 with bisphosphonates. 212 
 Discussion 213 
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This multicenter study was aimed to evaluate the phenotype of newly diagnosed PHPT in Italy, the adherence to the 214 
2013 International Guidelines for the management of asymptomatic PHPT and the rate of surgical cure of PHPT.  215 
PHPT was more frequent in females than males (M/F=4.9:1)), and most common in the 5th-6th decades of life, 216 
confirming the finding of a large (n=360) retrospective single-center Italian survey [15]. On the other hand, data 217 
retrieved from the “Record of Hospital Discharge” between 2006 and 2011 in 46275 Italian patients under the code  218 
“PHPT-related diagnoses and surgical procedures” showed a lower female-male ratio (2.2:1) [16].  It is of note that, 219 
under the above code, conditions other than PHPT could have been included, namely “non-tumor-related 220 
hypercalcemia”, “not-specified hyperparathyroidism” and “other PTx”, thus making this cohort not completely 221 
comparable with our series. In agreement with our data studies carried out in the USA and Brazil report a female-to-222 
male ratio of 3-4:1 [17, 18]. 223 
The clinical presentation of PHPT is highly variable all over the world. In industrialized countries, where automatic 224 
biochemical screening is routinely available, the disease is mainly asymptomatic and relevant bone and stone 225 
manifestations are unusual. In the present study, the majority of patients (54.2%) were asymptomatic, a percentage that 226 
is similar to that (47.8%) reported by Castellano  et al. in their retrospective study [15] and by Trombetti et al. (57%) in 227 
the prospective Swiss PHPT Cohort Study [19]. In USA, the rate of asymptomatic disease is even higher (80%) [3], 228 
while in other countries, like India or China, is very low (around 20%) [20].  229 
In the literature, the terms “mild” and “asymptomatic” are often used as synonymous, but not necessarily the latter 230 
patients with asymptomatic PHPT have a mild disease, since they may present moderate hypercalcemia, kidney stones, 231 
vertebral fractures accidentally discovered during evaluation, and osteoporosis. To overcome this issue, a recent 232 
consensus statement of Italian Society of Endocrinology recommends to define as “mild” patients with asymptomatic 233 
PHPT without surgical criteria [21].  234 
Recent studies have shown that, despite the change in the clinical profile of PHPT in Western Countries to a less severe 235 
disease, nephrolithiasis remains one of the features of classic PHPT in the modern cohorts. In the present study, we 236 
found an overall rate of nephrolithiasis of 29.1%, definitely lower than that (55%) reported in an Italian single-center 237 
study [22], but similar to the rate reported in the Swiss population (17%) [19]. The latter study also reported renal 238 
stones detected at ultrasound in 35% of patients with asymptomatic PHPT, a figure markedly higher than that (11.3%) 239 
reported by Castellano et al. in a retrospective study [23]. Unfortunately, in the present study the electronic CRF was 240 
not designed for differentiating silent from symptomatic kidney stones, nor for evaluation the urinary stone risk profile 241 
[9].  242 
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One of the major aims was to evaluate the adherence of Italian endocrinologists, who were directly involved in the 243 
decision-making process in this survey, to the international guidelines for the management of symptomatic and 244 
asymptomatic PHPT. Despite the availability of such guidelines since 1991, as well as positions statements of the two 245 
major Italian endocrine societies [24] with similar indications, we found that only about half of either symptomatic or 246 
asymptomatic patients who met the criteria for PTx underwent surgery. Our data confirm that there is still a suboptimal 247 
adherence to the guidelines, both in USA and Europe. Sharata et al., in a retrospective chart-review of 350 primary care 248 
clinicians in Oregon, USA, over the period 2009-2011, identified 124 patients with PHPT with no history of prior PTx. 249 
PTx was performed in 26/76 (34%) of patients who met criteria for surgery, either because symptomatic or 250 
asymptomatic with at least one criterion according to the 2013 guidelines, and in 12/48 (25%) who did not meet 251 
surgical criteria. In about half of cases endocrinologists participated in the treatment choice of most primary care 252 
physicians. Young age, hypercalciuria and, particularly history of nephrolithiasis were associated with surgery [25].  253 
Yeh et al. identified from the Southern California Kaiser-Permanente Laboratory Management System Patient Database 254 
3388 patients with all the following laboratory values: serum PTH >65 pg/mL, serum calcium >10.5 and serum 255 
creatinine >2.5 mg/dl between1995 and 2008. PTx was performed in 134 (50.6%) of 265 patients with symptomatic 256 
PHPT (nephrolithiasis) and in 830 (26.6%) of 3123 with asymptomatic PHPT. Of the remaining 3123 with 257 
asymptomatic PHPT 569 of 1362 (41.8%) of those who met the Consensus criteria for PTx and 469 of the 1761 258 
(26.6%) who did not were submitted to surgery. Serum calcium >11.5 mg/dL, 24-h urinary calcium excretion ≥ 400 mg 259 
and age >50 years were predictive of PTx [26].  FinallyAlso, even in the Swiss PHPT population, the guidelines 260 
adherence was similar to our results. Indeed, authors evaluated 332 patients, 143 (43%) with symptomatic disease and 261 
189 (57%) with asymptomatic and PTx was performed only in 71/143 (49.6%) symptomatic patients and in 82/131 262 
(62.3%) asymptomatic patients with at least one criterion for PTx [19].   263 
In an attempt to understand why the Italian endocrinologists did not advise PTx in about half of patients who met the 264 
current guidelines for surgery, either symptomatic or asymptomatic, we evaluated the role of all variables in the 265 
decision-making process. The finding of negative parathyroid imaging studies (concordant negative ultrasound and 266 
MIBI scan) strongly predicted the conservative approach. Older age and lower serum calcium concentrations were also 267 
independent predictors, but with a lower weight. A relevant role of negative parathyroid imaging studies in not advising 268 
PTx in patients with PHPT who met surgical criteria was reported by two recent European studies, both based upon 269 
questionnaire-based surveys. Villar del Moral et al. found that 11% of institutions considered PTx contraindicated in 270 
patients with asymptomatic PHPT and negative parathyroid imaging studies [27].  A similar attitude was adopted by 271 
15% of Spanish Hospital Endocrinology services [28]. It However, it is noteworthy that international guidelines clearly 272 
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suggest that negative imaging should not inhibit to refer the patient to an experienced parathyroid surgeon, available in 273 
Endocrinology third levels centers [13]. Moreover, it was recently demonstrated that preoperative negative imaging is 274 
not associated with a decreased surgical cure rate for PHPT primary hyperparathyroidism in a large PHPT population 275 
(2185 patients) [29].  276 
 277 
As stated by the International Guidelines and the Italian Consensus, PTx should be considered in all patients with 278 
asymptomatic PHPT, including those who did not meet the surgical criteria. In this regard it is worth noting that prior 279 
randomized clinical trials have shown an improvement in BMD and neuropsychiatric symptoms in those patients who 280 
underwent PTx, compared with those who did not PTx [30–32]. Of note in our study, 16 of 66 patients without surgical 281 
criteria underwent surgery, and interestingly, the majority of them had positive parathyroid imaging studies, likely 282 
accounted for recommending PTx in patients who did not meet the surgical criteria. In the study of Trombetti et all. 283 
11/59 patients without PTx criteria underwent surgery, mainly for the severe neuropsychological complains. 284 
Unfortunately, they had no data on parathyroid imaging [19].  285 
PTx was successful in almost all patients (94%) and this is in line with the results of a recent meta-analysis, which 286 
included 82 observational and 6 randomized studies and found a final cure rate of 97-98% [33] and with the prospective 287 
swiss study (97%) [19].  288 
Persistence of PHPT was observed in 10/168 (6.0%) cases. The persistence of PHPT ranges between 2 and 22% when 289 
considering all cases of PHPT [34] and 2.5-5%, when considering sporadic PHPT [35, 36]. Interestingly, all these 290 
patients had apparently sporadic PHPT, but 3 had a multiglandular disease at the histology:  (2 hyperplasia and 1 double 291 
adenoma). Accordingly to other studies, hyperplasia and double adenoma are associated with a significantly higher rate 292 
of persistence compared to single adenoma [34]. We cannot exclude that these 3 patients might be familial cases with 293 
insufficient family history information or “de novo” cases of familial forms of PHPT.  294 
Fourteen patients had hereditary PHPT, and only 4 of them underwent PTx during the one-year follow-up. This 295 
conservative approach in the hereditary forms of PHPT likely depends upon the higher rate of persistence/recurrence 296 
compared with sporadic PHPT, unless an extensive surgery, which is associated with a higher risk of complications, is 297 
performed. In this regard, Udelsman et al. underline that the surgical approach in hereditary PHPT should aim to 298 
achieve normocalcemia for as long as possible, minimizing complications. In this regard the patient’s desire and the 299 
surgeon’s experience, rather that the guidelines for surgery, could influence the therapeutic decision [13]. Interestingly 300 
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all 4 patients undergoing PTx were normocalcemic after surgery, even if the one-year follow is too short to consider 301 
them cured.  302 
The strengths of the study are: i) its prospective nature; ii) the inclusion of a large number of Italian Centers equally 303 
distributed in the Country; iii) the rather complete clinical, biochemical, instrumental data at baseline, and iv) the one-304 
year follow-up data after PTx or surveillance.  305 
This study has also some limitations: i) 11 out 29 centers did not participate in the one-year follow-up study; ii) all 306 
centers were third level referral centers, and iii) the short follow-up, iv) the lack of the intra and inter-assay coefficient 307 
of variation between the different centers is also a limit for biochemical analyses and densitometric data.. 308 
the laboratories measurements were not centrally made. . 309 
In conclusion, the present study indicates that Italian endocrinologists working in tertiary referral centers do not follow 310 
international guidelines for the management of PHPT. Parathyroid imaging studies are very often performed in the 311 
initial patient’s workout and negative findings are strong predictors of a non-surgical approach. PTx is successful in 312 
almost all patients. 313 
 314 
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 407 
Legend of Figure 408 
Fig. 1.  Flow chart of patients’ recruitment, treatment and follow-up. 409 
Abbreviations: PHPT, primary hyperparathyroidism; PTx, parathyroidectomy 410 
 According to the 2013 International Guidelines for the Management of Asymptomatic Primary 411 
Hyperparathyroidism 412 
 413 
 414 
 415 
Data Availability: The datasets generated during and/or analysed during the current study are available from 416 
the corresponding author on reasonable request. 417 
 418 
 419 
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Table 1: Clinical and biochemical data of patients in the whole group and in patients with available follow-up 
 Whole Group (n=604) Patients with 
available follow-up 
(n=345) 
P 
Number of participating Centers  29 18 - 
Sex  
          Females n (%) 
          Males   n (%) 
 
502 (83%) 
102 (17%) 
 
289 (83.8%) 
56 (16.2%) 
 
0.7 
Age at diagnosis (years) 61±14 63±13 0.06 
Diagnosis 
         Sporadic n (%) 
         Familial n (%) 
 
566 (93.7%) 
38 (6.7%) 
 
331 (95.9%) 
14 (4.1%) 
 
0.05 
         Asymptomatic, n (%) 
         Symptomatic, n (%) 
358 (59.3%) 
246 (40.7%) 
187 (54.2%) 
158 (45.8%) 
0.05 
Osteoporosis (T <-2.5 at any site) 264 (43.7%) 152 (44.1%) 0.8 
Clinical fractures, n (%) 70 (11.6%) 43 (12.5%) 0.6 
Nephrolithiasis, n (%) 177 (29.1%) 119 (34.5%) 0.02 
Neuropsychiatric symptoms, n (%) 60 (9.9%) 44 (12.7%) 0.07 
Symptoms of hypercalcemia, n (%) 34 (5.6%) 20 (5.8%) 0.5 
Albumin-adjusted serum calcium 
(mg/dL) 
10.9±1 10.8±1.3 0.4 
Plasma intact PTH (pg/mL) 163±173 152±141 0.2 
Serum 25OHD (ng/mL) 30±19 28±14 0.03 
Serum creatinine (mg/dl) 0.8±0.2 0.8±0.1 0.3 
Urinary calcium excretion (mg/24 h) 326±192 284±186 0.007 
Table Click here to download Table Table 1  20-11-17.docx 
             Table 2. Comparison between patients who underwent surgery or not in with symptomatic primary hyperparathyroidism (A), in 
asymptomatic patients with indications to parathyroidectomy (B) and the whole group of patients with indications to 
parathyroidectomy (C) 
 
A. Patients with symptomatic PHPT1 (n=158) 
 
Parameters PTx2 (n=87) No PTx (n=71) P 
Age at diagnosis (years) 56.9±13 65.6±12 0.007 
Albumin-adjusted serum calcium (mg/dL) 11.4±1.53 10.4±1.13 <0.001 
Plasma PTH (pg/mL) 228.6±225.2 10.5.7±66.8 <0.001 
Serum (25OHD) (ng/mL) 14.4±1.8 13.2±1.9 0.001 
Serum creatinine (mg/dl) 0.55±0.39 0.63±0.36 0.2 
Urinary calcium excretion (mg/24 h) 385.9±200.7 262.7±161 <0.001 
Serum calcium >1 mg/dl upper limit of normal 45 (51.7%) 7 (9.8%) 0.0001 
Osteoporosis (n%) 36 (41.4%) 33 (46.5%) 0.08 
Clinical fractures n (%) 12 (13.7%) 31 (43.6%) 0.001 
Nephrolithiasis n (%) 71 (81.6%) 23 (32.4%) 0.033 
Hypercalciuria (>400 mg/24h) n (%) 15 (17.2%) 8 (11.3%) 0.02 
Neuropsychiatric symptoms n (%) 15 (17.2%) 14 (19.7%) 0.4 
Symptoms of hypercalcemia n (%) 13 (14.9%) 7 (9.8%) 0.2 
B. Patients with asymptomatic PHPT and surgical criteria2 (n=121) 
 
 PTx (n=65) No PTx (n=56) P 
Age < 50 years 14 (21.5) 11 (16.9%) 0.4 
Serum calcium >1 mg/dL upper limit of normal 37 (56.9) 12 (21.4%) <0.0001 
Hypercalciuria (>400 mg/24h), n (%) 44 (67.7) 30 (53.6%) 0.08 
Osteoporosis, n (%) 41 (63.1) 38 (67.8%) 0.5 
Serum creatinine (mg/dl) 0.86±0.19 0.82±0.27 0.3 
C. Whole group of patients with PTx3 indications (n=279) 
 PTx (n=152) No PTx (n=127) P 
Sex (F:M) 5.7:1 4.7:1 0.3 
Age at diagnosis (years) 59.9±13.1 64.7±13.5 <0.001 
Albumin-adjusted serum calcium (mg/dL) 11.4±1.3 10.6±1 <0.001 
Table Click here to download Table Table 2  20-11-17.docx 
  
 
 
 
 
 
 
 
 
 
 
1 Primary hyperparathyroidism 
2 according to the 2013 International Guidelines for the Management of PHPT  
3 Parathyroidectomy 
 
Plasma intact PTH (pg/mL) 190±187 113±77 <0.001 
Serum 25(OH)D (ng/mL) 22.2±15.4 26.6±16.7 0.04 
Serum creatinine (mg/dl) 0.79±0.17 0.80±0.18 0.7 
Urinary calcium excretion (mg/24 h) 257.6±229.7 186.5±168.5 0.015 
Serum calcium >1 mg/dl upper limit of normal 82 (53.9%) 19 (14.9%) <0.001 
Osteoporosis (T <-2.5 at any site) 71 (46.7%) 82 (64.5%) 0.05 
Clinical fractures n (%) 13 (8.5%) 32 (25.2%) 0.001 
Nephrolithiasis n (%) 71 (46.7%) 48 (37.8%) 0.08 
Hypercalciuria (>400 mg/24h) n (%) 25 (16.4%) 11 (8.7%) 0.01 
Neuropsychiatric symptoms n (%) 15 (9.8%) 14 (11%) 0.4 
Symptoms of hypercalcemia n (%) 16 (10.5%) 14 (11%) 0.5 
 Table 3. Predictors for the choice of not performing Parathyroidectomy: Results 
of Logistic Regression Model 
Whole group of patients with criteria for Parathyroidectomy1 
Parameter Odd ratio 95% Wald Confidence 
Limits 
P value 
Age at diagnosis 1.031 1.007-1.055 0.010 
Albumin-adjusted serum 
calcium  
0.515 0.352-0.753 0.001 
Concordant negative 
imaging (ultrasound andor 
MIBI2 scan) negative 
11.753 5.078-27.205 <0.0001 
Asymptomatic patients  
 
Parameter Odd ratio 95% Wald Confidence 
Limits 
P value 
Albumin-adjusted serum 
calcium  
0.298 0.144-0.619 0.001 
Concordant negative 
imaging (ultrasound and 
MIBI2 scan)Either 
ultrasound or MIBI scan 
negative 
10.821 3.1-37.15 <0.0001 
Symptomatic patients  
 
Parameter Odd ratio 95% Wald Confidence 
Limits 
P value 
Age at diagnosis 1.048 1.009-1.088 0.016 
Albumin-adjusted serum 
calcium  
0.484 0.236-0.991 0.04 
Concordant negative 
imaging (ultrasound and 
MIBI2 scan)Either 
ultrasound or MIBI scan 
negative 
18.00 4.2-81 <0.0001 
1 according to the 2013 International Guidelines for the Management of PHPT (Bilezikian JP, Brandi ML, 
Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: 
Summary statement from the fourth international workshop. J Clin Endocrinol Metab. 
2014;99(10):3561-3569. 
2 99mTc-sestamibi parathyroid scintigraphy. 
Table Click here to download Table Table 3_19-03-18.docx 
 Table 4. Comparison between baseline and one-year follow-up data in patients followed without parathyroidectomy  
 
 
1 PTx =Parathyroidectomy, according to the 2013 International Guidelines for the Management of PHPT (Bilezikian JP, Brandi ML, Eastell R, et al. 
Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J Clin 
Endocrinol Metab. 2014;99(10):3561-3569. 
2one-year vs baseline evaluation 
 
 
 
 
 Symptomatic patients  
(n=71) 
Asymptomatic patients 
(n=106) 
   Without criteria for PTx1  
(n=50) 
With criteria for PTx  
(n=56) 
 Baseline 
evaluation 
One-year 
follow-up 
P 2 Baseline 
evaluation 
One-year 
follow-up 
P Baseline 
evaluation 
One-year 
follow-up 
P 
Serum albumin-adjusted 
calcium (mg/dL) 
10.4±1.1 10.9±0.6 0.3 9.6±1.7 10.2±0.6 0.2 10.3±0.7 10.3±0.7 0.7 
Plasma intact PTH 
(pg/mL) 
118.3±73 92.6±60.5 0.1 125.9±48.7 123.5±72.3 0.7 115±66 113±61 0.7 
Serum 25(OH)D 
(ng/mL) 
30.2±14.1 32.3±9.5 0.02 31.9±12.6 32.8±8.6 0.8 28.4±13 30.9±10 0.1 
Serum creatinine 
(mg/dl) 
0.65±0.32 0.82±0.24 0.09 0.65±0.36 0.65±0.33 0.6 0.68±0.35 0.69±0.4 0.5 
Urinary calcium excretion 
(mg/24 h) 
235.9±146.9 241.6±156.7 0.5 208.1±104.4 219.4±166.4 0.6 281.9±142.7 275.7±171 0.8 
Table Click here to download Table Table 4_20-11-17.doc 
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We thank the reviewers and the editor for their thoughtful comments that we took into account and made changes in the 
manuscript accordingly (see tracking in the text). 
 
EDITOR 
I think that, in order to compare the Italian picture with other countries, it might be useful to quote and discuss the 
following paper recently published in this journal: 
-Trombetti A et al: Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss 
Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms. J Endocrinol Invest 
2016; 39: 567-576. 
 
We kindly thank the editor for this noteworthy suggestion. We changed the text accordingly and compared our results to 
those of Trombetti et al. along all the Discussion section (see tracking). 
REVIEWER # 1 
In this study the Authors report on the results of a large Italian multicentre prospective study investigating 
laboratory, clinical and one-year follow-up data in patients with PHPT. The Authors investigate the adherence to the 
latest guideline of the Fourth International Workshop (2013) for the management of asymptomatic primary 
hyperparathyroidism. The main conclusions are as follows.  
1. Despite the clear suggestions of both the International and Italian guidelines, the adherence to them is weak 
both in the symptomatic and asymptomatic patients’ groups. 
2. Despite the lack being among the surgical criteria, the results of imaging studies are strong predictors of 
choice between surgical versus conservative approach both within the symptomatic and also asymptomatic 
patients groups.  
General remarks 
This is an important and worthwhile study to measure the impact of PHPT guidelines on the therapeutic decisions 
for PHPT patients regarding conservative vs. surgical approach.  
Major remarks 
-Approx. 43% of patients were lost for the one-year follow-up. Patients who were asymptomatic and had negative 
imaging are probably overrepresented in lost-to-follow-up group. The impact of the high rate of not being followed, 
as a study bias should be discussed.  
We thank the reviewer for this comment. Indeed, this group of patients was not lost at follow-up, but were patients of 
those centers which did not participate to the second part of the study (follow-up). It’s not possible to extrapolate the 
idea that they had a negative imaging rate higher than that of patients reported in the study. The Centers that 
participated at the second part of the study (18/29 as now clearer in the results section line ≠159) had few patients lost at 
follow-up.  Of note, the lower number of Centers participating the second part of the study is already reported in the 
limitations (end of discussion).  
2. The impact of the results of preoperative imaging investigations (ultrasound and MIBI-scintigraphy) is a very 
interesting although not unexpected result of the study. Throughout the manuscript, it is not always clear whether 
the positive/negative results mean completely negative/completely positive results. What about the discordant results? 
Were the discordant results considered as negative or positive?  
We thank the reviewer and apologize for the inaccuracy. The negative result means concordant negative imaging, i.e. 
both ultrasound and MIBI scan were negative. Indeed, we did not include the discordant imaging results because we 
think that we cannot draw conclusions from them. We now have clarified this point along the text and in the Table 3. 
Supplementary Material Click here to download Supplementary Material REVISIONE
JEI 15-3-18.doc
3. It would be worthwhile to discuss the (probably unjustified or at least too high) impact of preoperative imaging on 
the decision making process regarding the choice between conservative vs. surgical treatment.  
We completely agree with the reviewer and we added a paragraph (see tracking) in the discussion section, citing 
International Guidelines and a recent American paper by Wachel et al. on preoperative parathyroid imaging and the 
decision-making process.  
4. Since there are no data about the decision-making process and its main participants, the reviewer is not confirmed 
that the endocrinologists are the only (mainly?) responsible doctors for this low adherence.  
We thank the reviewer for the comment. Indeed, we believe that the endocrinologists are the direct responsible for 
decision making process in this study, since in all the third level referring centers included in the study, patients were 
referred and followed-up from specialists. However, also the patient’s desire could influence the therapeutic decision, 
but unfortunately, we have not these data, as already reported in the discussion (line ≠292). We clarify this point at line 
≠250-251.  
Minor remarks 
1. Despite the large number of patients with MEN1, no patients with MEN2. This needs explanation,  
We thank the reviewer for this comment. A possible explanation is that MEN2 patients are primarily referred to the 
oncology service of the Endocrinology Unit, where the preoperative evaluation is made for thyroid and parathyroid 
therapeutic program.  
2. The non-cure rate of 6% seems a bit high. This observation probably reflects the relatively high number of 
low-volume surgical institutions and would be worthwhile to analyse.  
We agree with to reviewer that the non-cure rate of 6% seems too high. However, interestingly, although defined as 
sporadic PHPT patients, 3 had a multiglandular disease and the histology showed hyperplasia in 2 cases and a double 
adenoma in one. Therefore, we can hypothesize that these patients might be familial cases with insufficient family 
history information or “de novo” cases of familial forms of PHPT, as stated in the discussion.  Of note, familial PHPT 
has a higher non cure rate than sporadic PHPT .  
4. Typing errors         
probably either instead of either line 184 ok 
Least instead of last Fig 1 ok 
 
REVIEWER # 2 
General Comments: 
This is an interesting paper focusing on PHPT clinical management among endocrinologists In Italy. The study 
demonstrates that a significant number of patients, either with or without symptoms are not managed according to 
clinical guidelines. Some observations ay help to improve the quality of the paper. 
 
Specific comments: 
- Page 5, Material and Methods: It is unclear if laboratory evaluations were made centrally or at the single sites 
only. If the latter to, how did the authors control for the potential and expected variability in terms of PTH and 
vitamin D assays particularly? 
We thank the reviewer for this important methodological clarification. The laboratory evaluation could not be done 
centrally, but we checked the relative uniformity of lab tests. Indeed, PTH assays were at least second or third 
generation and vitamin D assays were mainly CLIA in each center laboratory. We agree that the best would be to 
centrally perform the measurements, but we encountered many technical and logistic difficulties. We included this point 
in the study limitations (see discussion).  
-There are no data about the type of DXA machines used in the study, nor in terms of cross-calibration or normal 
data used to define patients as normal or osteoporotic. Please, consider this point carefully. 
We understand the point of the reviewer and agree that the centralization of the DXA data would have been the gold 
standard. However, this was not planned in this study. We added this point in the limitation of the study. All the 
participating centers were third level endocrinology units and used HOLOGIC or LUNAR DXA machines.  
The definition of osteoporosis was made accordingly to the latest international guidelines for osteoporosis (reference 
≠14). We included this clarification in the text in the Materials and Methods and Results sections. 
- The terms "fragility fractures" and "clinical fractures" need to be better defined. Clinical (symptomatic?) vertebral 
fractures were then confirmed by X-ray imaging? Which was the method to define a vertebral fracture? 
We thank the reviewer for this comment. Fragility fractures were defined as and synonymous of symptomatic.  We 
specified this point in the Materials and Methods section. 
 
-Table 1 and Table 2: Vitamin D levels were normal in the whole group of patients. Taking into account the very 
high prevalence of low vitamin D levels in Italy, this observation is rather strange. How can the authors explain the 
data? 
We thank the reviewer for this comment. The possible explanation is that the patients were supplemented with vitamin 
D supplement (by primary medical care), before reaching the endocrinologist. Indeed, the majority of the participating 
centers recorded the use of vitamin D supplements in the database.  
- Table 2: vitamin D levels were low in patients with symptoms, irrespective of PTx/no PTx. It seems also that only 
these patients had this problem (see before). Which is the explanation? Was Low Vitamin D a possible determinant 
of symptoms? 
We thank the reviewer for this comment. We agree with the reviewer that low vitamin D could be a determinant of 
symptoms. Indeed, hypovitaminosis seems to be more prevalent in patients with PHPTthan in geographically matched 
populations and correlates with severity of the disease (symptoms). Also the increased levels of 1,25-dihydroxyvitamin 
D in PHPT have also been proposed to influence overall vitamin D status. Possible mechanisms might include an 
inhibition of the production of vitamin D3 in skin, an inhibition of the production of 25-hydroxyvitamin D in the liver 
or increased renal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D and a shorter half-life of 25-
hydroxyvitamin, as discussed in the paper by Silverberg et al. JBMR 2007. 
